Log in

NASDAQ:IDRAIdera Pharmaceuticals Stock Price, Forecast & News

-0.01 (-0.57 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $1.73
50-Day Range
MA: $1.82
52-Week Range
Now: $1.73
Volume78,385 shs
Average Volume119,211 shs
Market Capitalization$58.30 million
P/E RatioN/A
Dividend YieldN/A
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.
Read More
Idera Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:IDRA



Sales & Book Value

Annual Sales$1.45 million


Net Income$-56,510,000.00


Market Cap$58.30 million
Next Earnings Date8/13/2020 (Estimated)

Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter.

Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

How has Idera Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Idera Pharmaceuticals' stock was trading at $1.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IDRA shares have increased by 25.4% and is now trading at $1.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Idera Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Idera Pharmaceuticals.

When is Idera Pharmaceuticals' next earnings date?

Idera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Idera Pharmaceuticals.

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals Inc (NASDAQ:IDRA) released its quarterly earnings results on Thursday, April, 30th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.06. View Idera Pharmaceuticals' earnings history.

When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work?

Idera Pharmaceuticals shares reverse split before market open on Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for IDRA?

3 brokers have issued 1 year target prices for Idera Pharmaceuticals' stock. Their forecasts range from $7.00 to $9.00. On average, they expect Idera Pharmaceuticals' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 362.4% from the stock's current price. View analysts' price targets for Idera Pharmaceuticals.

Has Idera Pharmaceuticals been receiving favorable news coverage?

News headlines about IDRA stock have trended extremely negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Idera Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutIdera Pharmaceuticals.

Are investors shorting Idera Pharmaceuticals?

Idera Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 421,600 shares, a decrease of 13.7% from the April 30th total of 488,800 shares. Based on an average trading volume of 204,200 shares, the short-interest ratio is currently 2.1 days. Approximately 1.8% of the company's shares are short sold. View Idera Pharmaceuticals' Current Options Chain.

Who are some of Idera Pharmaceuticals' key competitors?

What other stocks do shareholders of Idera Pharmaceuticals own?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the following people:
  • Mr. Vincent J. Milano, Pres, CEO & Director (Age 55)
  • Mr. John J. Kirby, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 47)
  • Dr. Jonathan Yingling, Sr. VP of Early Devel. & Chief Scientific Officer (Age 50)
  • Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 56)
  • Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 64)

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include DCF Advisers LLC (0.32%), Acadian Asset Management LLC (0.22%), JPMorgan Chase & Co. (0.19%), Two Sigma Advisers LP (0.16%) and Aperio Group LLC (0.06%). Company insiders that own Idera Pharmaceuticals stock include Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin, John J Kirby, Jonathan Michael Yingling, Robert C Fletcher and Vincent Milano. View institutional ownership trends for Idera Pharmaceuticals.

Which major investors are selling Idera Pharmaceuticals stock?

IDRA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, JPMorgan Chase & Co., and Two Sigma Advisers LP. Company insiders that have sold Idera Pharmaceuticals company stock in the last year include Bryant David Lim, Invest Corp Pillar, John J Kirby, Jonathan Michael Yingling, Robert C Fletcher, and Vincent Milano. View insider buying and selling activity for Idera Pharmaceuticals.

Which major investors are buying Idera Pharmaceuticals stock?

IDRA stock was bought by a variety of institutional investors in the last quarter, including DCF Advisers LLC, and Aperio Group LLC. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin, and Vincent Milano. View insider buying and selling activity for Idera Pharmaceuticals.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $1.73.

How big of a company is Idera Pharmaceuticals?

Idera Pharmaceuticals has a market capitalization of $58.30 million and generates $1.45 million in revenue each year. The biotechnology company earns $-56,510,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Idera Pharmaceuticals employs 36 workers across the globe.

What is Idera Pharmaceuticals' official website?

The official website for Idera Pharmaceuticals is www.iderapharma.com.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.